Acheiropodia

From WikiMD's WELLNESSPEDIA


Acheiropodia
Synonyms N/A
Pronounce N/A
Specialty N/A
Symptoms Congenital absence of hands and feet
Complications N/A
Onset Birth
Duration Lifelong
Types N/A
Causes Genetic mutation
Risks N/A
Diagnosis Clinical examination, Genetic testing
Differential diagnosis N/A
Prevention N/A
Treatment Supportive care
Medication N/A
Prognosis N/A
Frequency Rare disease
Deaths N/A


Acheiropodia is a rare genetic disorder characterized by the congenital absence of hands and feet. This condition is inherited in an autosomal recessive pattern and is caused by mutations in the LMBR1 gene.

Presentation[edit]

Individuals with acheiropodia are born without hands and feet, a condition known as amelia. The absence of these limbs is due to a disruption in the normal development of the limb bud during embryogenesis.

Genetics[edit]

Acheiropodia is caused by mutations in the LMBR1 gene, which is located on chromosome 7. This gene is involved in the sonic hedgehog signaling pathway, which plays a crucial role in the development of limbs. The condition follows an autosomal recessive inheritance pattern, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.

Diagnosis[edit]

Diagnosis of acheiropodia is primarily based on clinical examination and the characteristic absence of hands and feet. Genetic testing can confirm the diagnosis by identifying mutations in the LMBR1 gene.

Management[edit]

There is no cure for acheiropodia, and management focuses on supportive care to improve the quality of life for affected individuals. This may include the use of prosthetic devices, physical therapy, and occupational therapy to enhance mobility and independence.

Epidemiology[edit]

Acheiropodia is an extremely rare condition, with only a few cases reported in the medical literature. It is more commonly observed in certain isolated populations where consanguinity is more prevalent.

See also[edit]

References[edit]


External links[edit]

Acheiropodia[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.